
Durotimi AI is transforming early cancer detection through its AI-enabled platform, which allows healthcare providers to optimize consultations by analyzing signs, symptoms, and risk factors. The platform continuously learns from real-world data, enhancing diagnostic accuracy and promoting personalized treatment plans. With a focus on minimizing delays and errors in cancer diagnosis, Durotimi AI aims to empower physicians with comprehensive risk assessments, ultimately improving patient outcomes and saving lives. The company is positioned at the forefront of healthcare innovation, leveraging advanced technology to revolutionize cancer care.

Durotimi AI is transforming early cancer detection through its AI-enabled platform, which allows healthcare providers to optimize consultations by analyzing signs, symptoms, and risk factors. The platform continuously learns from real-world data, enhancing diagnostic accuracy and promoting personalized treatment plans. With a focus on minimizing delays and errors in cancer diagnosis, Durotimi AI aims to empower physicians with comprehensive risk assessments, ultimately improving patient outcomes and saving lives. The company is positioned at the forefront of healthcare innovation, leveraging advanced technology to revolutionize cancer care.
Headquarters: Dublin, Ireland
Focus: AI-driven early cancer detection and diagnostic support
Reported headcount: 11–50 employees
Recent funding: Non-equity assistance (AI Ecosystem Accelerator) announced 2024-10-09
Early cancer detection; diagnostic support for clinicians
Biotechnology